Back to Search
HOPE BROXTERMAN, PHARMD
PHARMD
Pharmacist
NPI: 1912349978Individual
Specialties, Licenses & Credentials
Research & Publications (20)
Cancer research 2000: drug resistance, new targets and drugs in development.
PMID 11498376·Drug Resist Updat·2000
8-other
Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib.
PMID 19212818·Angiogenesis·2009
8-other
Sunitinib-induced hemoglobin changes are related to the dosing schedule.
PMID 19188672·J Clin Oncol·2009
7-preclinical
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival.
PMID 18794101·Clin Cancer Res·2008
8-other
Angiogenesis inhibitors. Drug selectivity and target specificity.
PMID 17897024·Curr Pharm Des·2007
6-review
VEGFR2 expressing circulating (progenitor) cell populations in volunteers and cancer patients.
PMID 17721629·Thromb Haemost·2007
8-other
Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation.
PMID 17097285·Eur J Cancer·2007
7-preclinical
CD13/Aminopeptidase N overexpression by basic fibroblast growth factor mediates enhanced invasiveness of 1F6 human melanoma cells.
PMID 16685268·Br J Cancer·2006
8-other
Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
PMID 16154800·Drug Resist Updat·2005
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1105 SIXTH ST
TRAVERSE CITY, MI 49684 - Phone
- (231) 935-5000
Quick Facts
- NPI
- 1912349978
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile